< Back to situations

Get alerts on this situation

We’ll email you as it develops, and you can follow the whole thread from day one.

Unsubscribe anytime.

[SITUATION] · [ACTIVE]

2 clusters · 12 sources · 7 days · First seen 8 days ago · Last updated 1 day ago

Categories: BUSINESS

US biotech Q2 earnings reports

Entities: Alterity Therapeutics Ltd. · Daniel O’Day · Actinogen Medical Ltd. · Robert Bradway · Mesoblast Ltd.

Overview

In late July 2026 Biogen posted a modest 3% year‑over‑year revenue rise to $2.7 billion, driven by its multiple‑sclerosis drugs and newer products such as Skyclarys and Leqembi. A week later Amgen reported stronger Q2 performance, with revenue up 9% to $10.1 billion and earnings per share beating expectations, while Gilead Sciences announced an 8% increase in product sales to $7.8 billion, led by double‑digit growth in its HIV portfolio.

On 4 August 2026 Amgen confirmed its 9% sales growth, posted adjusted earnings of $6.29 per share, and raised its full‑year earnings outlook to $22.30‑$23.50 per share on revenue of $38.2‑$39.4 billion. The company also disclosed the discontinuation of its obesity drug candidate AMG 513. Gilead reiterated its adjusted loss of $6.75 per share, better than forecasts, and highlighted continued strength in HIV, liver‑disease, and oncology segments.

Other biotech peers reported mixed results: Geron recorded a Q2 loss of $16.7 million on $57.5 million revenue, driven by its oncology drug RYTELO; Rigel Pharmaceuticals earned $0.88 per share, beating expectations, with $67 million in commercial revenue; Precigen posted a modest EPS beat of $0.05 on $55 million revenue; and TG Therapeutics saw BRIUMVI sales jump 64% to $227.7 million. The series of reports underscores a broadly healthy earnings environment for major U.S. biotech firms in the second quarter of 2026.

Claims

What the coverage asserts, and how well corroborated each claim is across sources.

[● 4 SOURCES] Amgen's second-quarter sales rose 9% to $10.1 billion. (d6748728-7438-4d52-b660-c7a6b7622a95,1856f338-7fdc-4a1a-9c21-d4c7c0ef247f,b26c0141-e646-4169-b345-eb8c600559c3,32f45738‑)
[● 4 SOURCES] Amgen's adjusted earnings per share were $6.29, beating expectations of $5.62. (Reuters)
[● 4 SOURCES] Amgen's net earnings per share increased 65% to $4.37. (d6748728-7438-4d52-b660-c7a6b7622a95,1856f338-7fdc-4a1a-9c21-d4c7c0ef247f,b26c0141-e646-4169-b345-eb8c600559c3,32f45738‑)
[● 4 SOURCES] Amgen raised its full‑year earnings outlook to $22.30‑$23.50 per share on revenue of $38.2‑$39.4 billion. (d6748728-7438-4d52-b660-c7a6b7622a95,1856f338-7fdc-4a1a-9c21-d4c7c0ef247f,b26c0141-e646-4169-b345-eb8c600559c3,32f45738‑)
[● 4 SOURCES] Quarterly sales of Repatha were $953 million, up 37% YoY. (Reuters)
[● 4 SOURCES] Quarterly sales of Evenity were $714 million, up 38% YoY. (Reuters)
[● 4 SOURCES] Sales of Uplizna increased 90% to $335 million. (Reuters)
[● 4 SOURCES] Amgen discontinued development of obesity candidate AMG 513. (Reuters)
[○ 1 SOURCE] Gilead Sciences' second‑quarter sales rose 8% to $7.8 billion, beating the $7.4 billion estimate. (31d70563-b5b6-45af-9a37-7826e02457d8)
[○ 1 SOURCE] Gilead's adjusted loss per share was $6.75, better than the $7.24 expected. (31d70563-b5b6-45af-9a37-7826e02457d8)
[○ 1 SOURCE] TG Therapeutics' BRIUMVI revenue jumped 64% to $227.7 million in Q2 2026. (96b31d56-af48-4862-9756-3106b29ee4cd)

Timeline

1 day ago

[BUSINESS] 10 sources
Amgen posts 9% Q2 sales growth and earnings beat as biotech peers report results
Amgen posted 9% Q2 sales growth to $10.1 bn, earnings beat and raised outlook; Gilead posted 8% sales rise, other biotech firms reported mixed Q2 results.
8 days ago

[BUSINESS] 2 sources
Biogen posts strong Q2 earnings as Australian biotech firms report solid quarterly results
Biogen beats Q2 forecasts with $2.7 bn revenue, while Australian biotech firms Mesoblast, Actinogen and Alterity report solid earnings and cash positions.

Sources

apen.be · europesays.com · kfgo.com · levisonenterprises.com · mommygearest.com · pulse2.com · stockhead.com.au · stocknews.com · wixx.com · wsau.com · wtvbam.com · wxerfm.com

This summary has been updated 2 times: see revision history